Form 4: Lilly Endowment Sells Over $100M Eli Lilly Shares

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 95,766 shares of common stock for over $100 million on November 21, 2025, executed under a Rule 10b5-1 trading plan.

Summary

• Lilly Endowment Inc., identified as a 10% owner of Eli Lilly & Co. (LLY), sold a total of 95,766 shares of common stock.
• The transactions occurred on November 21, 2025, and were reported on November 24, 2025.
• The shares were sold in multiple transactions at weighted average prices ranging from $1,050.272 to $1,066.15 per share.
• The estimated total value of the shares sold exceeds $100 million.
• Following these sales, Lilly Endowment Inc. beneficially owns 92,501,978 shares of Eli Lilly & Co. common stock.
• The sales were conducted pursuant to a Rule 10b5-1(c) trading plan, indicating a pre-scheduled and non-discretionary transaction.

Sentiment

Score: 5

Explanation: The sale of a significant number of shares by a 10% owner could be seen as slightly negative, but the execution under a Rule 10b5-1 plan mitigates this, suggesting a pre-planned rebalancing rather than a loss of confidence. Therefore, the sentiment is neutral.

Positives

• The sales were executed under a Rule 10b5-1 trading plan, which suggests a pre-planned, non-discretionary transaction rather than a reaction to new, negative information about the company.

Negatives

• A significant sale of 95,766 shares by a 10% owner, even under a 10b5-1 plan, represents a reduction in their stake, which could be interpreted as a slight negative signal by some investors.

Future Outlook

NA

Industry Context

This filing reports an insider transaction for a major pharmaceutical company. Such transactions are routine and do not inherently reflect broader industry trends, though the company's performance within the industry would influence its stock price.

Related Party Transactions

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., sold common stock of the issuer. This transaction itself is a related party transaction.

Stakeholder Impact

• Shareholders: The sale by a significant institutional shareholder could slightly increase the float of shares available in the market. While a large sale might raise questions, the 10b5-1 plan context suggests it is not a signal of declining confidence in the company's future.

Key Dates

Keywords

Eli Lilly, LLY, Lilly Endowment, SEC Form 4, insider trading, stock sale, beneficial ownership, Rule 10b5-1, pharmaceuticals, biotechnology